New hope for tough nasopharyngeal cancer: Triple-Drug combo trial launches
NCT ID NCT07581821
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) in 33 adults with recurrent or metastatic nasopharyngeal cancer that has not responded to prior immunotherapy. The goal is to see if this combo can shrink tumors or control the disease. Participants must be 18-65 and have failed at least one prior standard treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC NASOPHARYNGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fifth Affiliated Hospital of Sun Yat-sen University Zhuhai, Guangdong, China, 519000
RECRUITINGZhuhai, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug combo targets Hard-to-Treat nasopharyngeal cancer
- Two-Antibody combo takes on advanced cancers
- New drug shows promise for Hard-to-Treat throat cancer
- New cocktail of drugs shows promise for Hard-to-Treat throat cancer
- New drug cocktail aims to outdo chemo for tough throat cancer
- New hope for advanced nose and throat cancer with combo therapy